Travere Therapeutics, Inc. TVTX EBIT

EBIT at other companies

Vertex PharmaceuticalsVRTX

$1.25B+8.3%

Jade BiosciencesJBIO

-$43.45M-85.8%

Vera TherapeuticsVERA

-$125.13M-119%

Eton Pharmaceuticals, Inc.ETON

$2.41M+614%

Viridian Therapeutics, Inc.VRDN

-$126.27M-18.3%

ANI PharmaceuticalsANIP

$40.46M+191%

FAQ

What is Travere Therapeutics, Inc.'s EBIT?

Travere Therapeutics, Inc. (TVTX) reported EBIT of -$36.92M in Q1 2026.

How has Travere Therapeutics, Inc.'s EBIT changed year-over-year?

Travere Therapeutics, Inc.'s EBIT increased by 13.5% year-over-year, from -$42.67M to -$36.92M.

What is the long-term trend for Travere Therapeutics, Inc.'s EBIT?

Over 4 years (2021 to 2025), Travere Therapeutics, Inc.'s EBIT has grown at a -25.1% compound annual growth rate (CAGR), from -$199.43M to -$62.82M.

What does EBIT mean?

Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.